Abstract
This study examines the efficacy of rifampin bonding to a gelatin-sealed knitted Dacron graft to prevent perioperative bacteremic vascular graft infection. Antibiotic bonding was obtained by soaking grafts for 15 minutes in a 1 mg/ml saline solution of rifampin at 37°C. Nineteen dogs had thoracoabdominal aortic bypass: seven (group I) received a rifampin treated graft; six (group II) received an untreated gelatin-coated graft; and six (group III) received an uncoated Dacron graft. Two days later bacteremic challenge was produced by rapid intravenous injection of 5×10 5 colony forming units of methicillin resistantStaphylococcus aureus.Grafts were harvested five days after this challenge and cut into 10 fragments, each submitted to bacterial counts. Results were expressed as CFU/cm 2 of graft material. In group I, no graft was infected, whereas all grafts in groups II and III were infected (p<0.05). Median bacterial counts from the infected fragments (median±SD) were similar in groups II (2.5×105 CFU/cm2) and III (4×104 CFU/cm2). Blood cultures at time of sacrifice were negative in all dogs in group I and positive in five of six dogs in groups II and III. Cultures of liver, spleen, kidney, and lung specimens were always negative in group I and positive in 22 of 24 specimens in group II and 23 of 24 specimens in group III. Soaking a gelatin-sealed Dacron graft in rifampin solution evidently prevents early bacteremic graft infection and secondary foci of infection in this model.
Similar content being viewed by others
References
KAISER AB, CLAYSON KR, MULHERIN JL, et al. Antibiotic prophylaxis in vascular surgery.Ann Surg 1978;188:283–289.
BUNT TJ. Synthetic vascular graft infections. I. Graft infections.Surgery 1983;93:733–746.
GOEAU-BRISSONNIERE O, PECHERE JC, LEPORT C. Comment prévenir les infections de prothèse. In: KIEFFER E (Ed).Les anévrismes de l'aorte abdominale sous-rénale. Paris: AERCV, 1990, pp 143–153.
GOLDSTONE J, MOORE WS. Infection in vascular prostheses. Clinical manifestations and surgical management.Am J Surg 1974;128:225–233.
LIEKWEG WJ, GREENFIELD LJ. Vascular prosthetic infections: collected experience and results of treatment.Surgery 1977;81:335–342.
LORENTZEN JE, NIELSEN OM, ARENDRUP H, et al. Vascular graft infection an analysis of 62 graft infections in 2411 consecutively implanted synthetic vascular graft.Surgery 1975;78:211–216.
SZYLAGYI DE, SMITH RF, ELLIOTT JP, et al. Infection in arterial reconstruction with synthetic grafts.Ann Surg 1972;176:321–333.
HARVEY RA, GRECO RS. The noncovalent bonding of antibiotics to a polytetrafluoroethylene-benzalkonium graft.Ann Surg 1981;194:642–647.
HARVEY RA, ALCID DV, GRECO RS. Antibiotic bonding to polytetrafluoroethylene with tridodecylmethylammonium chloride.Surgery 1982;92:504–512.
HARVEY RA, TESORIERO JV, GRECO RS. Noncovalent bonding of penicillin and cefazolin to Dacron.Am J Surg 1984;147:205–209.
HENRY R, HARVEY RA, GRECO RS. Antibiotic bonding to vascular prostheses.J Thorac Cardiovasc Surg 1981;82:272–277.
GRECO RS, HARVEY RA, SMILOW PC. Prevention of vascular prosthetic infection by a benzalkonium-oxacillin bonded polytetrafluoroethylene graft.Surg Gynecol Obstet 1982;155:28–32.
GRECO RS, TROOSKIN SZ, DOUETZ AP, et al. The application of antibiotic bonding to the treatment of established vascular prosthetic infection.Arch Surg 1985;120:71–75.
PRAHLAD A, HARVEY RA, GRECO RS. Diffusion of antibiotics from a polytetrafluoroethylene-benzalkonium surface.Ann Surg 1981;194:515–518.
MOORE WS, CHVAPIL M, SEIFFERT G, et al. Development of an infection-resistant vascular prosthesis.Arch Surg 1981;116:1403–1407.
BENVENISTY AI, TANNENBAUM G, AHLBORN TN, et al. Control of prosthetic bacterial infection: evaluation of an easily incorporated tightly bonded silver antibiotic PTFE graft.J Surg Res 1988;44:1–7.
MODAK SM, SAMPATH L, FOX CL, et al. A new method for the direct incorporation of antibiotic in prosthetic vascular grafts.Surg Gynecol Obstet 1987;164:143–147.
WHITE JV, BENVENISTY AI, REEMTSMA K, et al. Simple methods for direct antibiotic protection of synthetic vascular grafts.J Vasc Surg 1984;1:372–380.
POWELL TW, BURNHAM SJ. A passive system using rifampin to create an infection-resistant vascular prosthesis.Surgery 1983;94:765–769.
YATES SG, BARROS D'SA AAB, BERGER K, et al. The preclotting of porous arterial prostheses.Ann Surg 1978;188:611–622.
GOEAU-BRISSONNIERE O, PECHERE JC, GUIDOIN R, et al. Experimental colonization of vascular grafts with Staphylococcus aureus.Can J Surg 1983:26:540–545.
BUCKELS JAC, FIELDING JWL, BLACK J, et al. Significance of positive bacterial cultures from aortic aneurysm contents.Br J Surg 1985;72:440–442.
MACBETH GA, RUBIN JR, MC INTYRE KE. The relevance of arterial wall microbiology to the treatment of prosthetic graft infections: graft infection vs arterial infection.J Vasc Surg 1984;1:750–756
CLARK RE, MARGRAF HW. Antibacterial vascular grafts with improved thrombo-resistance.Arch Surg 1974;109:159–162.
THORNSBERRY C, HILL BC, SWENSON JM, et al. Rifampin: spectrum of antibacterial activity.Rev Infect Dis 1983;5 (Suppl 3):S412-S419.
HARTMANN G, HONIKEL KO, KUNSEL F, et al. The specific inhibition of the DNA-directed RNA synthesis by erythromycin.Biochem Biophys Acta 1967;145:843–844.
ACAR F, GOLDSTEIN FW, DUVAL J. Use of rifampin for the treatment of serious staphylococcal and Gram-negative infections.Rev Infec Dis 1983;5 (Suppl 3):S502-S507.
KUNIN CM, BRANDT O, WOOD HG. Bacteriologic studies of rifampin: a new semi-synthetic antibiotic.J Infect Dis 1969;119:132–138.
SANDE SA. The use of rifampin in the treatment of nontuberculous infections: an overview.Rev Infect Dis 1983;5 (Suppl 3);S399-S411.
MANDELL GL, VENT KT. Killing of intraleucocytic Staphylococcus aureus by rifampin: in vitro and in vivo studies.J Infect Dis 1972;125:486–489.
DICKINSON JP, MITCHISON DA, LEE SK. Serum rifampicin concentration related to dose size and to the incidence of the “flu syndrome” during intermittent rifampin administration.J Antimicrob Chemother 1977;3:445–452.
POOLE G, STRADLING P, WORLLEDGE S. Potentially serious side effects of high dose twice-weekly rifampin.Bio Med J 1974;3:343–347.
GROSSET J, LEVENTIS S. Adverse effects of rifampin.Rev Infect Dis 1983;5 (Suppl 3);S440-S450.
ASHTON TR, CUNNINGHAM JD, PATON D, et al. Antibiotic loading of vascular grafts. Proceedings of the 16th Annual Meeting of the Society for Biomaterials, Charleston, South Carolina, pp 235, May 20–23, 1990.
JONAS RA, ZIENER G, SCHOEN FJ, et al. A new sealant for knitted Dacron prostheses minimally cross-linked gelatin.J Vasc Surg 1988;7:414–419.
Author information
Authors and Affiliations
About this article
Cite this article
Goëau-Brissonnière, O., Leport, C., Bacourt, F. et al. Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed dacron graft. Annals of Vascular Surgery 5, 408–412 (1991). https://doi.org/10.1007/BF02133043
Issue Date:
DOI: https://doi.org/10.1007/BF02133043